IGM Biosciences
IGMIGM Biosciences, Inc. (NASDAQ: IGM) is a clinical-stage biotechnology company based in the United States. The company's primary business focus is the development of engineered immunoglobulin M (IgM) antibodies for therapeutic applications. Unlike most antibody therapies that utilize IgG antibodies, IGM's platform is designed to exploit the structural and functional properties of IgM, which is the largest antibody class naturally produced by the human immune system. This approach aims to create multivalent antibodies with high binding strength and distinct mechanisms of action. The company's pipeline is concentrated in two key therapeutic areas: oncology and autoimmune diseases. Its lead oncology candidate, imvotamab, is a bispecific IgM antibody targeting CD20 and CD3, and is being evaluated in clinical trials for various B cell malignancies. Another candidate, aplitabart, is an IgM antibody targeting DR5 for the treatment of solid tumors. In autoimmune and inflammatory diseases, IGM is developing IgM antibodies targeting key cytokines such as IL-6R and the KLH IgE allergen. As a publicly traded entity, IGM Biosciences advances its research and development programs through clinical trials. The company's work is based on the scientific premise that engineered IgM antibodies may offer differentiated therapeutic profiles compared to established IgG-based approaches.
IGM · Stock Price
Historical price data
About
IGM Biosciences, Inc. (NASDAQ: IGM) is a clinical-stage biotechnology company based in the United States. The company's primary business focus is the development of engineered immunoglobulin M (IgM) antibodies for therapeutic applications. Unlike most antibody therapies that utilize IgG antibodies, IGM's platform is designed to exploit the structural and functional properties of IgM, which is the largest antibody class naturally produced by the human immune system. This approach aims to create multivalent antibodies with high binding strength and distinct mechanisms of action. The company's pipeline is concentrated in two key therapeutic areas: oncology and autoimmune diseases. Its lead oncology candidate, imvotamab, is a bispecific IgM antibody targeting CD20 and CD3, and is being evaluated in clinical trials for various B cell malignancies. Another candidate, aplitabart, is an IgM antibody targeting DR5 for the treatment of solid tumors. In autoimmune and inflammatory diseases, IGM is developing IgM antibodies targeting key cytokines such as IL-6R and the KLH IgE allergen. As a publicly traded entity, IGM Biosciences advances its research and development programs through clinical trials. The company's work is based on the scientific premise that engineered IgM antibodies may offer differentiated therapeutic profiles compared to established IgG-based approaches.